Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

AstraZeneca announced the company has submitted a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorisation Application to the European Medicines Agency for an investigational drug, vandetanib 100 mg for use in combination with chemotherapy for the treatment of advanced non–small cell lung cancer in patients previously treated with one prior anti–cancer therapy. The U.S. and European submissions are supported by data from Phase III clinical studies evaluating the safety and efficacy of vandetanib 100 mg in combination with chemotherapy. Pending approval, the treatment will be marketed as ZACTIMA.

Today in Chemotherapy/Oncology...keeping you current

Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09

N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09

Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09

Today in Drug Approvals...keeping you current

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address